2016
DOI: 10.1016/bs.mie.2016.01.011
|View full text |Cite
|
Sign up to set email alerts
|

Chemical Biology Approaches for Characterization of Epigenetic Regulators

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
5
0

Year Published

2016
2016
2022
2022

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 5 publications
(5 citation statements)
references
References 50 publications
0
5
0
Order By: Relevance
“…Treatment of SCs with Noggin (Prepotech) or DKK1 (Prepotech) was done at 100 ng/ml concentration. SCs and SC-derived primary myoblasts were treated with 1 μM of chemical probes provided by the Structural Genomics Consortium (SGC, http://www.thesgc.org/chemical-probes/epigenetics) 29,30 . OICR-9429 and Bromodomain Inhibitors were originally described in 19,31–39.…”
Section: Methodsmentioning
confidence: 99%
“…Treatment of SCs with Noggin (Prepotech) or DKK1 (Prepotech) was done at 100 ng/ml concentration. SCs and SC-derived primary myoblasts were treated with 1 μM of chemical probes provided by the Structural Genomics Consortium (SGC, http://www.thesgc.org/chemical-probes/epigenetics) 29,30 . OICR-9429 and Bromodomain Inhibitors were originally described in 19,31–39.…”
Section: Methodsmentioning
confidence: 99%
“…Indeed, it is extremely unlikely that two compounds with distinct chemical scaffolds would both bind not only the same target but also the same off-target. For instance, treatment with the SMYD2 inhibitor LLY-507 (Table ) results in loss of cell viability and apoptosis of glioblastoma primary cells; however, this phenotype is not reproduced with Bay-598, a chemically distinct SMYD2 inhibitor, indicating that the cytotoxicity of LLY-507 is an off-target effect . Developing two unrelated chemical probes for the same target is demanding from a medicinal chemistry perspective, but our data indicates that this additional effort is justified.…”
Section: Negative Controls Have a High Chance To Not Bind Off-targetsmentioning
confidence: 84%
“…For instance, treatment with the SMYD2 inhibitor LLY-507 (Table 1) results in loss of cell viability and apoptosis of glioblastoma primary cells; however, this phenotype is not reproduced with Bay-598, a chemically distinct SMYD2 inhibitor, indicating that the cytotoxicity of LLY-507 is an off-target effect. 23 Developing two unrelated chemical probes for the same target is demanding from a medicinal chemistry perspective, but our data indicates that this additional effort is justified. When available, medicinal chemists should consider progressing multiple hits from a primary screening campaign toward the development of more than one chemical probe.…”
Section: ■ Negative Controls Have a High Chance To Not Bind Off-targetsmentioning
confidence: 88%
“…Utilising a previously established serum-free, growth factor-enriched spheroid culture that enriches for CC-ICs in patient-derived CRC samples 17 , we screened a collection of 22 selective chemical probes that inhibit epigenetic regulatory proteins using viable cell count as a readout (Supplementary Figure 1a). Each probe was used at a single concentration aiming for an estimated cellular IC 90 concentration 18 (Fig. 1a, Supplementary Table 1).…”
Section: Resultsmentioning
confidence: 99%